Compare Marsh & McLennan Companies, Inc. (MRSH) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Smith & Nephew plc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $86.15B), while Smith & Nephew plc trades at $27.96 (market cap $11.63B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| MRSH | SNN | |
|---|---|---|
Market Cap | $86.15B | $11.63B |
Sector | Financials | Health |
52-Week High | $207.02 | $38.53 |
52-Week Low | $157.32 | $27.80 |
Enterprise Value | $106.83B | $14.66B |
Dividend Yield | 2.19% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The company shows solid fundamentals with revenue growth to $26.98B in 2025 and consistent earnings beats. Analyst consensus is a Buy with a $208.63 price target, though sentiment is mixed with 66.7% Hold ratings. Recent news highlights expansion in cyber protection services and insights on healthcare cost trends.
The outlook remains positive given strong profitability and strategic initiatives, but risks include economic sensitivity and competitive pressures. The stock offers upside to the consensus target, supported by institutional interest and stable cash flows, though high valuation multiples warrant caution amid market volatility.
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
